U.S. Lysosomal Storage Disorder Drugs Market to 2032
Overview
The U.S. Lysosomal Storage Disorder Drugs Market is expected to reach a 7.34 USD Billion by 2032 and is projected to grow at a CAGR of 11.27% from 2025 to 2032.
Revenue, 2024 (USD Billion)
3.47
Forecast, 2032 (USD Billion)
7.34
CAGR, 2024 - 2032
11.27%
Report Coverage
U.S.
U.S. Lysosomal Storage Disorder Drugs Market 2018-2032 USD Billion
U.S. Lysosomal Storage Disorder Drugs Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 3.47 USD Billion
- Projected Market Size (2032): 7.34 USD Billion
- CAGR (2025-2032): 11.27%
Key Findings of U.S. Lysosomal Storage Disorder Drugs Market
- The U.S. Lysosomal Storage Disorder Drugs Market was valued at 3.47 USD Billion in 2024.
- The U.S. Lysosomal Storage Disorder Drugs Market is likely to grow at a CAGR of 11.27% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Hospital Pharmacies in Distribution Channel Segment accounted for the largest share of the market with a revenue of 2.36 USD Billion
- The fastest growing segment Imiglucerase in Drugs Segment grew Fastest with a CAGR of 14.46% during the forecast period from 2024 to 2032.
U.S. Lysosomal Storage Disorder Drugs Market Scope
U.S. Lysosomal Storage Disorder Drugs Market Segmentation & Scope
Distribution Channel
- Online Pharmacies
- Drugs Stores and Retail Pharmacies
- Hospital Pharmacies
Type of Disorder
- Others
- Krabbe Disease
- Niemann-Pick Disease
- Mucopolysaccharidosis (MPS)
- Pompe Disease
- Fabry Disease
- Gaucher Disease
Type
- Others
- Chaperone Therapy
- Substrate Reduction Therapy (SRT)
- Enzyme Replacement Therapy (ERT)
Gender
- Female
- Male
Drugs
- Others
- Avalglucosidase Alfa
- Galsulfase
- Agalsidase Alpha
- Laronidase
- Taliglucerase Alfa
- Velaglucerase
- Alglucosidase Alpha
- Idursulfase
- Agalsidase Beta
- Imiglucerase
Route of Administration
- Others
- Oral
- Subcutaneous (SC)
- Intravenous (IV)
Age Group
- Geriatric
- Adults
- Pediatric
U.S. Lysosomal Storage Disorder Drugs Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2023 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 3.47 USD Billion |
| Market Value in 2032 | 7.34 USD Billion |
| CAGR (2025-2032) | 11.27% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Distribution Channel,Type of Disorder,Type,Gender,Drugs,Route of Administration,Age Group |
Regional Insights:
-
Leading Market (2024-2032): U.S., leading in terms of revenue 3.47 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 3,474.73 USD Million in 2024.
Segments and Scope
-
U.S. Lysosomal Storage Disorder Drugs Market to 2032, By Distribution Channel
- Hospital Pharmacies is the largest segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 2.36 USD Billion in the year 2024.
- Online Pharmacies is the Fastest growing segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 11.43 % in forecast period 2025-2032.
-
U.S. Lysosomal Storage Disorder Drugs Market to 2032, By Type of Disorder
- Gaucher Disease is the largest segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 1.15 USD Billion in the year 2024.
- Gaucher Disease is the Fastest growing segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 12.42 % in forecast period 2025-2032.
-
U.S. Lysosomal Storage Disorder Drugs Market to 2032, By Type
- Enzyme Replacement Therapy (ERT) is the largest segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 2.23 USD Billion in the year 2024.
- Substrate Reduction Therapy (SRT) is the Fastest growing segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 11.10 % in forecast period 2025-2032.
-
U.S. Lysosomal Storage Disorder Drugs Market to 2032, By Gender
- Male is the largest segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 1.89 USD Billion in the year 2024.
- Male is the Fastest growing segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 12.19 % in forecast period 2025-2032.
-
U.S. Lysosomal Storage Disorder Drugs Market to 2032, By Drugs
- Imiglucerase is the largest segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 702.24 USD Billion in the year 2024.
- Imiglucerase is the Fastest growing segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 14.46 % in forecast period 2025-2032.
-
U.S. Lysosomal Storage Disorder Drugs Market to 2032, By Route of Administration
- Intravenous (IV) is the largest segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 1.97 USD Billion in the year 2024.
- Subcutaneous (SC) is the Fastest growing segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 10.57 % in forecast period 2025-2032.
-
U.S. Lysosomal Storage Disorder Drugs Market to 2032, By Age Group
- Pediatric is the largest segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 1.41 USD Billion in the year 2024.
- Pediatric is the Fastest growing segment in U.S. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 12.49 % in forecast period 2025-2032.
U.S. Lysosomal Storage Disorder Drugs Market Company Share Analysis
| Company Name |
|
||
| Takeda Pharmaceutical Company Limited | |||
| Pfizer Inc. | |||
| Sanofi | |||
| BioMarin | |||
| Amicus Therapeutics, Inc. | |||
U.S. Lysosomal Storage Disorder Drugs Market Geographical Sales Distribution, 2018-2032 USD Billion
U.S. Lysosomal Storage Disorder Drugs Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The U.S. Lysosomal Storage Disorder Drugs Market is segmented based on Segmentation Distribution Channel,Type of Disorder,Type,Gender,Drugs,Route of Administration,Age Group.
U.S. Lysosomal Storage Disorder Drugs Market was valued at USD 3.47(Revenue in USD Billion) in 2023.
U.S. Lysosomal Storage Disorder Drugs Market is projected to grow at a CAGR of 11.27% during the forecast period of 2024 to 2032.
The Hospital Pharmacies segment is expected to dominate the U.S. Lysosomal Storage Disorder Drugs Market, holding a largest market share of 2.36 USD Billion in 2024
U.S. Lysosomal Storage Disorder Drugs Market Scope
U.S. Lysosomal Storage Disorder Drugs Market Segmentation & Scope
Distribution Channel
- Online Pharmacies
- Drugs Stores and Retail Pharmacies
- Hospital Pharmacies
Type of Disorder
- Others
- Krabbe Disease
- Niemann-Pick Disease
- Mucopolysaccharidosis (MPS)
- Pompe Disease
- Fabry Disease
- Gaucher Disease
Type
- Others
- Chaperone Therapy
- Substrate Reduction Therapy (SRT)
- Enzyme Replacement Therapy (ERT)
Gender
- Female
- Male
Drugs
- Others
- Avalglucosidase Alfa
- Galsulfase
- Agalsidase Alpha
- Laronidase
- Taliglucerase Alfa
- Velaglucerase
- Alglucosidase Alpha
- Idursulfase
- Agalsidase Beta
- Imiglucerase
Route of Administration
- Others
- Oral
- Subcutaneous (SC)
- Intravenous (IV)
Age Group
- Geriatric
- Adults
- Pediatric
Frequently Asked Questions
The U.S. Lysosomal Storage Disorder Drugs Market is segmented based on Segmentation Distribution Channel,Type of Disorder,Type,Gender,Drugs,Route of Administration,Age Group.
U.S. Lysosomal Storage Disorder Drugs Market was valued at USD 3.47(Revenue in USD Billion) in 2023.
U.S. Lysosomal Storage Disorder Drugs Market is projected to grow at a CAGR of 11.27% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Lysosomal Storage Disorder Drugs Market for final year is USD 7.34 (USD Billion).
U.S. Lysosomal Storage Disorder Drugs Market Company Profiling
Frequently Asked Questions
The U.S. Lysosomal Storage Disorder Drugs Market is segmented based on Segmentation Distribution Channel,Type of Disorder,Type,Gender,Drugs,Route of Administration,Age Group.
U.S. Lysosomal Storage Disorder Drugs Market was valued at USD 3.47(Revenue in USD Billion) in 2023.
U.S. Lysosomal Storage Disorder Drugs Market is projected to grow at a CAGR of 11.27% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Lysosomal Storage Disorder Drugs Market for final year is USD 7.34 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.